Accessibility Menu

Bausch Health Companies(FRA) BVF

Market Cap€1.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
€5.20
+0.78%
+0.04Today

Bausch Health Companies Financials at a Glance

Market Cap

€1.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€9.31K

Net Income (TTM)

-€933.15

EPS (TTM)

-€2.53

P/E Ratio

-2.03

Dividend

€0.00

Beta (Volatility)

0.03 (Low)

Price

€5.20

Volume

0

Open

€5.20

Previous Close

€5.16

Daily Range

€5.20 - €5.20

52-Week Range

€3.66 - €6.57

Estimated Earnings Date

N/A

BVF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bausch Health Companies

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refer to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologics, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Industry

Pharmaceuticals

Employees

20,300

CEO

Thomas J. Appio

BVF Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-49.26%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€1.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

373.99M

Volume

0

Avg. Volume

47.242

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Bausch Health Companies Performance Analysis

Bausch Health Companies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 7,729,970,0598.3%
20232023-12-31EUR 8,099,966,3464.8%
20242024-12-31EUR 8,898,106,9169.9%
20252025-12-31EUR 9,096,403,1282.2%
Bausch Health Companies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -0.59-73.5%
20232023-12-31EUR -1.50153.7%
20242024-12-31EUR -0.12-92.3%
20252025-12-31EUR 0.37N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€2.45K

+1.1%

Gross Profit

€1.60K

+1.2%

Gross Margin

65.04%

+1.1%

Market Cap

€1.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€0.07

N/A

Employees

20,300

N/A

Net Income

€223.62

+2.0%

EBITDA

€908.22

+1.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€19.78K

-1.1%

Total Debt

€18.17K

+1.0%

Accounts Receivable

€1.98K

+1.1%

Inventory

€1.40K

+1.0%

Long Term Debt

€17.40K

+1.0%

Short Term Debt

€770.58

+1.0%

Return on Assets

-4.17%

-11.7%

Return on Invested Capital

-1.49%

+0.7%

Free Cash Flow

€507.80

+3.7%

Operating Cash Flow

€573.86

+2.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
WETOWetour Robotics
$5.48-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$71.92+0.00%
IBITiShares Bitcoin Trust
$44.67+0.02%
INTCIntel
$89.51+0.00%

Questions About BVF

What is the current price of Bausch Health Companies?

Bausch Health Companies is trading at €5.20 per share.

What is the 52-week range for Bausch Health Companies?

Over the past 52 weeks, Bausch Health Companies has traded between €3.66 and €6.57.

How much debt does Bausch Health Companies have?

As of the most recent reporting period, Bausch Health Companies reported total debt of €18.17B.

How much cash does Bausch Health Companies have on hand?

Bausch Health Companies reported €1.61B in cash and cash equivalents in its most recent financial results.

What is Bausch Health Companies’s dividend yield?

Bausch Health Companies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.